Compare · BNTX vs ELUT
BNTX vs ELUT
Side-by-side comparison of BioNTech SE (BNTX) and Elutia Inc. (ELUT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BNTX and ELUT operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- BNTX is the larger of the two at $22.27B, about 684.2x ELUT ($32.6M).
- BNTX has been more active in the news (11 items in the past 4 weeks vs 1 for ELUT).
- BNTX has more recent analyst coverage (25 ratings vs 0 for ELUT).
- Company
- BioNTech SE
- Elutia Inc.
- Price
- -
- -
- Market cap
- $22.27B
- $32.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 11
- 1
- Recent ratings
- 25
- 0
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small cell lung cancer.It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II a clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody, which is in Phase I/IIa clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Genevant Sciences GmbH; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Latest BNTX
- SEC Form 6-K filed by BioNTech SE
- BioNTech Provides Update on Phase 2/3 Clinical Trial for mRNA Cancer Immunotherapy Candidate BNT113 in Metastatic HPV16-positive Head and Neck Cancer
- SEC Form 4 filed by BioNTech SE
- Argus initiated coverage on BioNTech
- SEC Form 4 filed by BioNTech SE
- SEC Form 4 filed by BioNTech SE
- Chief Executive Officer Sahin Ugur sold $3,301,068 worth of Ordinary Shares (34,000 units at $97.09) as part of a pre-agreed trading plan, decreasing direct ownership by 16% to 180,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,480,659 worth of Ordinary Shares (66,000 units at $98.19) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 214,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,012,500 worth of Ordinary Shares (61,000 units at $98.57) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 280,209 units (SEC Form 4)
- Chief Executive Officer Sahin Ugur sold $6,842,742 worth of Ordinary Shares (69,000 units at $99.17) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 341,209 units (SEC Form 4)
Latest ELUT
- Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029
- CHIEF SCIENTIFIC OFFICER Williams Michelle Leroux converted options into 12,500 shares and covered exercise/tax liability with 4,269 shares, increasing direct ownership by 7% to 126,283 units (SEC Form 4) (tax liability)
- CHIEF FINANCIAL OFFICER Ferguson Matthew converted options into 12,500 shares and covered exercise/tax liability with 4,486 shares, increasing direct ownership by 2% to 489,903 units (SEC Form 4) to cover withholding tax
- PRESIDENT AND CEO Mills C Randal converted options into 27,083 shares and covered exercise/tax liability with 9,718 shares, increasing direct ownership by 4% to 464,395 units (SEC Form 4) (tax liability)
- Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th
- Elutia to Participate in the Lake Street Capital Markets 10th Annual Big Ideas Growth Conference & the H.C. Wainwright 28th Annual Global Investment Conference
- Elutia Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
- Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc.
- Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch
- SEC Form S-8 filed by Elutia Inc.